Clinical Trial Detail

NCT ID NCT02074839
Title Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Agios Pharmaceuticals, Inc.
Indications

hematologic cancer

Therapies

Ivosidenib

Age Groups: adult senior

Additional content available in CKB BOOST